From Signal to Cure: How AI is Ending the "Trial-and-Error" of Modern Medicine скачать в хорошем качестве

From Signal to Cure: How AI is Ending the "Trial-and-Error" of Modern Medicine

In this episode of the GSD Presents Silicon Valley AI & Tech series, we sit down with the visionary founders of Matrix Edge Therapeutics, Elaine Phan and Andreas Taylor. We dive deep into how they are building the "Signal → Cure → Longevity" AI infrastructure to revolutionize drug discovery and patient stratification. Learn how continuous patient signals and agentic AI are being used to reduce clinical trial-and-error, speed up cure development, and ultimately extend human healthspan. Key Topics Covered: The shift from reactive medicine to AI-driven Precision Medicine. How "Continuous Patient Signals" improve subtyping and stratification. The role of AI in streamlining the lifecycle from drug discovery to post-market management. The future of longevity and bio-tech innovation. About the Guests: Elaine Phan: Founder of Matrix Edge Therapeutics, Biopharma leader (20+ years), NIH AI strategist, and UC Berkeley/Stanford/Georgia Tech alumna. Andreas Taylor: Co-Founder & CTO, Genentech veteran, Data Scientist, and expert in agentic AI applications and drug delivery. Connect with GSD Venture Studios: gsdvs.com #PrecisionMedicine #AIinHealthcare #Longevity #DrugDiscovery #Biotech #GSDVS #TopGlobalStartups #HealthTech #BioPharma